Inflammation plays a central role in many chronic health conditions, and a 2022 scientific review examined how cannabinoids found in medical cannabis may help regulate inflammatory responses throughout the body. The authors reviewed evidence on major cannabinoids including CBD, THC, CBG, CBC, and CBN, highlighting their ability to interact with the endocannabinoid system and other cellular signaling networks involved in immune function. The review found that cannabinoids can influence the production of inflammatory molecules, immune cell activity, and oxidative stress, making them a growing area of interest in inflammation research.

The article explains that cannabinoids work through several different mechanisms rather than a single pathway. Researchers found evidence that cannabinoids may reduce the release of pro-inflammatory cytokines, regulate immune cell responses, limit oxidative damage, and influence receptors involved in pain and inflammation signaling. The review also noted that different cannabinoids appear to have distinct biological effects, suggesting that individual compounds may offer unique therapeutic advantages depending on the condition being studied.

The authors concluded that cannabinoids demonstrate significant anti-inflammatory potential across a wide range of preclinical and clinical research. However, they emphasized the need for additional human studies to establish optimal dosing, long-term safety, and condition-specific treatment approaches. The review highlights cannabinoids as promising therapeutic agents whose anti-inflammatory effects may contribute to future treatments for inflammatory and immune-related disorders.

Source: Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Medical Cannabis Activity Against Inflammation: Active Compounds and Modes of Action. Biomedicine & Pharmacotherapy. 2022. Available at: https://pubmed.ncbi.nlm.nih.gov/35614947/